tisagenlecleucel CAR-T
Selected indexed studies
- Current Progress in CAR-T Cell Therapy for Solid Tumors. (Int J Biol Sci, 2019) [PMID:31754328]
- CAR T-cell therapy for B-cell lymphoma. (Curr Probl Cancer, 2022) [PMID:35012754]
- Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma. (Expert Opin Biol Ther, 2023) [PMID:37599463]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Current Progress in CAR-T Cell Therapy for Solid Tumors. (2019) pubmed
- CAR T-cell therapy for B-cell lymphoma. (2022) pubmed
- Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing. (2025) pubmed
- Impact of Manufacturing Procedures on CAR T Cell Functionality. (2022) pubmed
- CAR T-Cells. (2020) pubmed
- Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma. (2023) pubmed
- From bench to bedside: the history and progress of CAR T cell therapy. (2023) pubmed
- CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia. (2018) pubmed
- CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. (2021) pubmed
- Kymriah® (tisagenlecleucel) - An overview of the clinical development journey of the first approved CAR-T therapy. (2023) pubmed